Cargando…

Long-term prophylaxis of hereditary angioedema with danazol

Detalles Bibliográficos
Autores principales:	Xu, Yingyang, Zhi, Yuxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945483/ https://www.ncbi.nlm.nih.gov/pubmed/36583927 http://dx.doi.org/10.1097/CM9.0000000000002144

Ejemplares similares

The effect of long-term danazol treatment on haematological parameters in hereditary angioedema
por: Kőhalmi, Kinga Viktória, et al.
Publicado: (2016)

Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema
por: Rahal, Soraya, et al.
Publicado: (2014)

Does hereditary angioedema make COVID-19 worse?
por: Xu, Yingyang, et al.
Publicado: (2020)

Mutation update of SERPING1 related to hereditary angioedema in the Chinese population
por: Wang, Xue, et al.
Publicado: (2022)

Health-related quality of life and its risk factors in Chinese hereditary angioedema patients
por: Liu, Shuang, et al.
Publicado: (2019)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Microbiota dysbiosis in hereditary angioedema patients
por: Özdemir, Öner
Publicado: (2023)

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022)

Validation of diagnostic and predictive biomarkers for hereditary angioedema via plasma N‐glycomics
por: Zhang, Zejian, et al.
Publicado: (2021)

Altered Urinary Metabolomics in Hereditary Angioedema
por: Wang, Xue, et al.
Publicado: (2022)

Informed decision‐making in hereditary angioedema prophylaxis
por: Burnette, Autumn Ford
Publicado: (2021)

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
por: Craig, Timothy, et al.
Publicado: (2017)

Throat microbiota alterations in patients with hereditary angioedema
por: Wang, Xue, et al.
Publicado: (2022)

Case report: follow-up of long term prophylaxis of hereditary angioedema with an alternative attenuated androgenic drug
por: Tebyrica, João
Publicado: (2015)

The natural course of hereditary angioedema in a Chinese cohort
por: Cao, Yang, et al.
Publicado: (2020)

Hereditary Angioedema with Normal C1 Esterase Inhibitor Refractory to Long-Term Prophylaxis: A Case Report
por: Cobb, Gavin, et al.
Publicado: (2023)

Short-term Prophylaxis for Delivery in Pregnant Women with Hereditary Angioedema with Normal C1-Inhibitor
por: Moraes, Caroline Guth de Freitas Batista de, et al.
Publicado: (2020)

The establishment and utility of Sweha-Reg: a Swedish population-based registry to understand hereditary angioedema
por: Mallbris, Lotus, et al.
Publicado: (2007)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Hereditary angioedema patients would prefer newer-generation oral prophylaxis
por: Geba, Daniela, et al.
Publicado: (2021)

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema
por: Gower, Richard G., et al.
Publicado: (2021)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis
por: Mendivil, Joan, et al.
Publicado: (2023)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Hereditary Angioedema: Not An Allergy
por: Bhivgade, Sanjay, et al.
Publicado: (2012)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

Pediatric hereditary angioedema
por: MacGinnitie, Andrew J
Publicado: (2014)

Hereditary angioedema in childhood
por: Ahn, Young Min
Publicado: (2020)

Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema
por: Anderson, John, et al.
Publicado: (2022)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
por: Soteres, Daniel F., et al.
Publicado: (2021)

Real-Life Experience With Subcutaneous Plasma-Derived C1-Inhibitor for Long-Term Prophylaxis in Patients With Hereditary Angioedema: A Case Series
por: Zanichelli, Andrea, et al.
Publicado: (2022)

Development of hepatocellular carcinoma after long-term immunosuppressive therapy including danazol in a dog
por: KOBAYASHI, Kosuke, et al.
Publicado: (2016)

Outcomes of long term treatments of type I hereditary angioedema in a Turkish family
por: Akoglu, Gulsen, et al.
Publicado: (2017)

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
por: Levy, Donald, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ptff9ib9qbhflc74qlk3vhc34m